CUDA

Research use only, not for human use.

CUDA is an effective soluble cyclohydrolase inhibitor with IC50 of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively.

CUDA is an effective soluble cyclohydrolase inhibitor with IC50 of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively. CUDA selectively increases the activity of peroxisome proliferator-activated receptor (PPAR) alpha. CUDA may be valuable for the study of cardiovascular diseases.(In Vitro):CUDA (10 μM; 18 hours) produced a 6-fold and 3-fold increase of PPARalpha in COS-7 cells. CUDA does not change the expression of PPARalpha protein. It competitively inhibits the binding of Wy-14643 (pirinixic acid) to the ligand binding domain of PPARalpha, indicating that it acts as a PPARalpha ligand.

CUDA (10 μM; 18 hours) produces 6- and 3-fold increases of PPARalpha in COS-7 cells.CUDA does not alter PPARalpha protein expression, and it competitively inhibits the binding of Wy-14643 (pirinixic acid) to the ligand binding domain of PPARalpha, suggesting that it functions as a PPARalpha ligand. Western Blot Analysis Cell Line:COS-7 cells Concentration:10 μM Incubation Time:18 hours Result:Activated PPARα by binding to the ligand binding domain of PPARα.

——

——

Metabolic Enzyme/Protease

PPAR

——

——

——

479413-68-8

340.508

C19H36N2O3

>98% (HPLC)

In Vitro:?DMSO : 25 mg/mL (73.42 mM)

OC(=O)CCCCCCCCCCCNC(=O)NC1CCCCC1

——

(-20℃)

With Ice Pack

≥ 2 years